C

Cencora

Global pharmaceutical distribution and services provider

Senior Account Executive

Full-TimeUpdated on 10/1/2026
$74k - $105.8k/yr
Mid
Remote in USA
RemoteTravel, including overnight travel, is required within the assigned customer base and geographic territory.

About the job

Requirements
  • Ability to communicate effectively, both orally and in writing.
  • Excellent integration, implementation, and management skills.
  • Excellent interpersonal skills.
  • Working knowledge of computers necessary to operate effectively with company systems and programs.
  • Excellent customer service skills to address potential issues through Customer Care channels without compromising selling-focused conversations.
  • Excellent follow-up skills to ensure practical follow-through.
  • Strong presentation skills.
  • Strong time management skills and ability to schedule customer appointments and calls in advance.
  • Advanced understanding of financial concepts relevant to maximizing sales profit, including profit and loss statements and value.
  • Ability to work independently with strong organizational skills and self-starter capability.
  • Willingness to travel and attend client meetings, trade shows, and company meetings or training sessions.
  • Advanced working knowledge of the company's programs and solutions that can offer increased customer value and enhance customer retention.
  • Strong organizational skills and attention to detail.
  • Ability to build strong in-person customer relationships.
  • Good decision-making skills.
  • Advanced knowledge of the hospital systems market.
  • Strong consultative selling and sales analytical skills.
  • Demonstrated initiative in professional development and business curiosity through keeping abreast of industry changes using industry information and company literature.
Responsibilities
  • Lead the client-facing relationship with all levels of pharmacy and supply-chain organizations, using active listening and advanced probing skills.
  • Promote and consultatively sell distribution and other solutions to expand business with existing health-systems customers within a specific geographic area, and identify and bring on new business.
  • Demonstrate a deep understanding of client needs when engaging economic influencers, pharmacy and supply-chain stakeholders, and C-suite contacts.
  • Own the renewal, new-business, and request-for-proposal processes, including identifying customer priorities, developing proposals, pricing, negotiating deals, and completing transactions.
  • Organize and conduct quarterly client business reviews aligned with the client's strategic priorities.
  • Increase distribution revenue and profit through account penetration and development of productive business relationships that identify opportunities and challenges addressable through company programs, solutions, and services.
  • Develop and maintain territory and account plans aligned with revenue, profitability, and sales goals.
  • Develop and deliver tailored, professional presentations to existing customers using a consultative selling approach that articulates the value the company can provide.
  • Own revenue and profitability objectives for assigned accounts and implement growth-driving opportunities for each client.
  • Collaborate with internal resources during the sales process to execute sales expansion and maintenance strategies using services and solutions tailored to customer needs.
  • Identify potential new customers within the territory and work with subject-matter experts to assess account needs, design consultative sales strategies, secure requests for proposals, negotiate terms, and bring on new business.
  • Maintain account activity and results information and track customer interactions in Salesforce, Altify, and other sales or customer relationship management tools.
  • Manage the assigned territory through a regular call cycle that delivers defined customer contacts, along with discretionary calls as situations require.
  • Travel as required, including overnight travel, within the assigned customer base and geographic territory, and attend conferences and sales meetings.
  • Perform related duties as assigned.

About the company

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.